Literature DB >> 18299685

The kidney in thrombotic thrombocytopenic purpura.

H-M Tsai1.   

Abstract

The kidney is commonly affected in thrombotic thrombocytopenic purpura (TTP), a multi-system disorder with microvascular thrombosis of the capillaries and arterioles. Nevertheless, due to difference in its diagnostic criteria, the frequency and severity of renal dysfunction in TTP remains controversial. Recent studies indicate that the severe deficiency of a von Willebrand factor (VWF) cleaving protease, ADAMTS13, is the main cause of platelet thrombosis in TTP; it is now possible to define TTP at the molecular level. Among patients with acquired TTP due to inhibitory antibodies of ADAMTS13, renal dysfunction is usually mild; oliguria, fluid overload, hypertension, and need of dialysis support are infrequent. When any of these complications occur, one must re-examine the diagnosis of TTP and consider the possibility that the patient has another cause for these complications. In a patient with hereditary TTP, acute renal failure may ensue. However, the renal dysfunction is mostly reversible if the patients are promptly treated with plasma to replenish ADAMTS13. Patients with TTP, particularly of the hereditary type, may develop chronic renal failure. This complication may be a consequence of repeated insults by overt or subclinical microvascular thrombosis to the kidney, or it may have a separate cause. Therapy of hereditary TTP should aim not only to prevent acute exacerbations but also to minimize the risk of irreversible renal injury.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18299685      PMCID: PMC2430013     

Source DB:  PubMed          Journal:  Minerva Med        ISSN: 0026-4806            Impact factor:   4.806


  114 in total

1.  Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias.

Authors:  Sarah L Allford; Beverley J Hunt; Peter Rose; Samuel J Machin
Journal:  Br J Haematol       Date:  2003-02       Impact factor: 6.998

2.  Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13.

Authors:  Xinglong Zheng; Kenji Nishio; Elaine M Majerus; J Evan Sadler
Journal:  J Biol Chem       Date:  2003-06-05       Impact factor: 5.157

3.  ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13.

Authors:  Gerhard Antoine; Klaus Zimmermann; Barbara Plaimauer; Monika Grillowitzer; Jan-Dirk Studt; Bernhard Lämmle; Friedrich Scheiflinger
Journal:  Br J Haematol       Date:  2003-03       Impact factor: 6.998

4.  Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai; Keith Shulman
Journal:  Eur J Haematol       Date:  2003-03       Impact factor: 2.997

5.  ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activity.

Authors:  Sureyya Savasan; Soon-Ki Lee; David Ginsburg; Han-Mou Tsai
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113

6.  ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage.

Authors:  Kenji Soejima; Masanori Matsumoto; Koichi Kokame; Hideo Yagi; Hiromichi Ishizashi; Hiroaki Maeda; Chikateru Nozaki; Toshiyuki Miyata; Yoshihiro Fujimura; Tomohiro Nakagaki
Journal:  Blood       Date:  2003-07-17       Impact factor: 22.113

7.  Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome.

Authors:  Antonella Lattuada; Edoardo Rossi; Cinzia Calzarossa; Rosaria Candolfi; Pier Mannuccio Mannucci
Journal:  Haematologica       Date:  2003-09       Impact factor: 9.941

8.  Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency.

Authors:  Karin Assink; Rikke Schiphorst; Sarah Allford; Diana Karpman; Amos Etzioni; Bénédicte Brichard; Nicole van de Kar; Leo Monnens; Lambertus van den Heuvel
Journal:  Kidney Int       Date:  2003-06       Impact factor: 10.612

Review 9.  Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases.

Authors:  Gregory A Hosler; Ana M Cusumano; Grover M Hutchins
Journal:  Arch Pathol Lab Med       Date:  2003-07       Impact factor: 5.534

10.  ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.

Authors:  Sara K Vesely; James N George; Bernhard Lämmle; Jan-Dirk Studt; Lorenzo Alberio; Mayez A El-Harake; Gary E Raskob
Journal:  Blood       Date:  2003-03-13       Impact factor: 22.113

View more
  11 in total

1.  The application of vWF/ADAMTS13 in essential hypertension.

Authors:  Wei-Hong Ma; Lin Sheng; Hui-Ping Gong; Lin-Lin Guo; Qing-Hua Lu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura.

Authors:  Marie Scully; Paul Knöbl; Karim Kentouche; Lawrence Rice; Jerzy Windyga; Reinhard Schneppenheim; Johanna A Kremer Hovinga; Michiko Kajiwara; Yoshihiro Fujimura; Caterina Maggiore; Jennifer Doralt; Christopher Hibbard; Leah Martell; Bruce Ewenstein
Journal:  Blood       Date:  2017-09-14       Impact factor: 22.113

Review 3.  Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Kidney Int Suppl       Date:  2009-02       Impact factor: 10.545

4.  ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment.

Authors:  Erica Rurali; Federica Banterla; Roberta Donadelli; Elena Bresin; Miriam Galbusera; Sara Gastoldi; Flora Peyvandi; Mary Underwood; Giuseppe Remuzzi; Marina Noris
Journal:  Clin J Am Soc Nephrol       Date:  2015-09-04       Impact factor: 8.237

Review 5.  Thrombotic microangiopathy and associated renal disorders.

Authors:  Thomas Barbour; Sally Johnson; Solomon Cohney; Peter Hughes
Journal:  Nephrol Dial Transplant       Date:  2012-07       Impact factor: 5.992

6.  Reference range for ADAMTS13 antigen, activity and anti-ADAMTS13 antibody in the healthy adult Singapore population

Authors:  Allison Ching Yee Tso; Christina Lai Lin Sum; Kiat Hoe Ong
Journal:  Singapore Med J       Date:  2020-06-26       Impact factor: 3.331

7.  Reduced cleavage of von willebrand factor by ADAMTS13 is associated with microangiopathic acute kidney injury following trauma.

Authors:  William E Plautz; Shannon H Haldeman; Mitchell R Dyer; Jason L Sperry; Francis X Guyette; Patricia A Loughran; Jurgis Alvikas; Adnan Hassoune; Lara Hoteit; Nijmeh Alsaadi; Brian S Zuckerbraun; Marian A Rollins-Raval; Jay S Raval; Roberto I Mota; Matthew D Neal
Journal:  Blood Coagul Fibrinolysis       Date:  2022-01-01       Impact factor: 1.061

Review 8.  The Glomerular Endothelium Restricts Albumin Filtration.

Authors:  Barbara J Ballermann; Jenny Nyström; Börje Haraldsson
Journal:  Front Med (Lausanne)       Date:  2021-11-29

9.  Long term follow up of congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) on hemodialysis for 19 years: a case report.

Authors:  Koki Mise; Yoshifumi Ubara; Masanori Matsumoto; Keiichi Sumida; Rikako Hiramatsu; Eiko Hasegawa; Masayuki Yamanouchi; Noriko Hayami; Tatsuya Suwabe; Junichi Hoshino; Naoki Sawa; Kenichi Ohashi; Koichi Kokame; Toshiyuki Miyata; Yoshihiro Fujimura; Kenmei Takaichi
Journal:  BMC Nephrol       Date:  2013-07-20       Impact factor: 2.388

10.  What is the impact of blood pressure on neurological symptoms and the risk of ESKD in primary and secondary thrombotic microangiopathies based on clinical presentation: a retrospective study.

Authors:  Jean-Michel Halimi; Benjamin Thoreau; Florent von Tokarski; Adeline Bauvois; Juliette Gueguen; Nicolas Goin; Christelle Barbet; Sylvie Cloarec; Elodie Mérieau; Sébastien Lachot; Denis Garot; Adrien Lemaignen; Emmanuel Gyan; Franck Perrotin; Claire Pouplard; François Maillot; Philippe Gatault; Bénédicte Sautenet; Emmanuel Rusch; Véronique Frémeaux-Bacchi; Cécile Vigneau; Guillaume Bayer; Fadi Fakhouri
Journal:  BMC Nephrol       Date:  2022-01-20       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.